TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 43 filers reported holding TERNS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,304,259 | +158.0% | 259,296 | +348.7% | 0.00% | – |
Q2 2023 | $505,593 | -52.2% | 57,782 | -35.3% | 0.00% | – |
Q1 2023 | $1,057,359 | +859.1% | 89,304 | +724.6% | 0.00% | – |
Q4 2022 | $110,249 | +57.5% | 10,830 | -9.1% | 0.00% | – |
Q3 2022 | $70,000 | +70.7% | 11,916 | -28.2% | 0.00% | – |
Q2 2022 | $41,000 | -16.3% | 16,588 | +1.0% | 0.00% | – |
Q1 2022 | $49,000 | -54.6% | 16,427 | +8.0% | 0.00% | – |
Q4 2021 | $108,000 | – | 15,208 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 6,657,992 | $33,489,700 | 3.67% |
ACUTA CAPITAL PARTNERS, LLC | 555,260 | $2,792,958 | 1.87% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 6,041,910 | $30,390,807 | 1.64% |
VR Adviser, LLC | 3,092,273 | $15,554,133 | 1.64% |
Fairmount Funds Management LLC | 2,040,000 | $10,261,200 | 1.24% |
Decheng Capital Management III (Cayman), LLC | 714,285 | $3,592,854 | 1.20% |
Deep Track Capital, LP | 6,000,000 | $30,180,000 | 1.16% |
Orbimed Advisors | 7,619,135 | $38,324,249 | 0.81% |
SILVERARC CAPITAL MANAGEMENT, LLC | 500,000 | $2,515,000 | 0.76% |
GREAT POINT PARTNERS LLC | 645,899 | $3,248,872 | 0.59% |